companies who have sought to develop inhibitors against these immune checkpoints in the tumor environment. PD-1 and PD-L1 are the most popular immune checkpoints that have been investigated and inhibitors against them have been subject to late-stage clinical testing or approved for clinical treatment for some other malignant tumors, such as lung cancer, melanoma and breast cancer. [8] [9] [10] B7-H3, also known as CD276, is an immune checkpoint, which belongs to the immunoglobulin superfamily, and is thought to participate in the regulation of T cell-mediated immune response. Studies been carried out on B7-H3 in many other cancers, including ovarian cancer, 11 colon cancer, 12 prostate cancer 13 and hepatocellular carcinomas 14 . It is reported that B7-H3 is universally expressed at a relatively higher level in more malignant tumor entities than in less malignant or benign tumors. These studies suggested that B7-H3 expression was associated with the extent of tumor malignancy, rationalizing the development of inhibitors against B7-H3.
Enoblituzumab, also referred to as MGA271, is a humanized IgG1κ monoclonal antibody recognizing B7-H3, which is reported to exhibit potent antitumor activity in B7-H3-expressing xenograft models of renal cell and bladder carcinomas. 15 Enoblituzumab is also used being used in clinical trials to treat refractory cancers, and has the potential to impact significantly on the clinical management of those diseases.
To the best of our knowledge, the molecular and clinical pattern of B7-H3 expression has not been fully characterized in gliomas of all grades. In this study, we set out to comprehensively delineate the molecular pattern and clinical relevance of B7-H3 in gliomas, using RNA-Seq data from the Chinese Glioma Genome Atlas (CGGA) dataset. RNA-Seq data for glioma samples from the TCGA dataset were used as a validation cohort. This is the first comprehensive study characterizing the molecular and clinical pattern of B7-H3 expression in whole grade gliomas.
| MATERIALS AND METHODS

| Sample and data collection
From the CGGA dataset, we collected RNA-Seq data (RPKM value) for 325 samples, ranging from WHO grade II to grade IV. 16 In the TCGA dataset, RNA-Seq data (level 3, RSEM normalized data) were available for 669 samples. Upon analyzing the RNA-Seq data, the RPKM value of the CGGA dataset and the RSEM value of the TCGA dataset were all log2 transformed. Written informed consent was obtained from patients for the CGGA project. This study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
| Detection of isocitrate dehydrogenase mutation
Isocitrate dehydrogenase (IDH) gene mutations are increasingly being recognized as the earliest mutation event in the development of diffuse gliomas and have been included in the most recent updated WHO classification of brain tumors. 17 IDH1/2 mutations are the most common genotype in gliomas, especially in lower-grade gliomas and secondary glioblastomas, which develop from lower-grade lesions. In the CGGA cohort, IDH1/2 mutations were detected by pyrosequencing as described in our previous study. 18 For the TCGA cohort, IDH mutation data were obtained from whole exon sequencing data or pyrosequencing.
| Definition of immune pathways
Immune pathways were defined with specific or groups of related gene ontology terms. Regulation of the T-cell receptor signaling pathway was defined with the term GO:0050856. 
| Statistical analysis
R language was used for performing statistical analysis and graphical work. 19 The HTSAnalyzeR package was used to perform gene ontology and pathway analysis. 20 Kaplan-Meier plots were generated with the survival package, 21 25 As expected, higher B7-H3 expression was correlated with higher grade, which indicated a malignant biological property in both CGGA and TCGA cohorts (Student's t test, Figure 1A& B) . To validate what we found, another 2 independent cohorts, CGGA microarray dataset and GSE16011 dataset, were also enrolled in this study and similar results were yielded ( Figure S1A&B ). Moreover, compared to normal brain tissues, tumor samples demonstrated significantly upregulated B7-H3 expression (Student's t test), suggesting the adverse role of this checkpoint in glioma development and progression. In subtypes, B7-H3 was upregulated in classical and mesenchymal subtypes, especially in mesenchymal subtypes in both CGGA and TCGA subtypes (Student's t test, Figure 1C&D ). This particular pattern of expression has been reported in our previous study, 7 
| B7-H3 expression is significantly associated with IDH isocitrate dehydrogenase mutation in high-grade gliomas
Isocitrate dehydrogenase mutation has been widely acknowledged as 
| B7-H3 is possibly regulated by methylation and microRNA-29 family at different stages, respectively
To elucidate the puzzle outlined in the above paragraph, we obtained methylation data and microRNA sequencing data for the TCGA lower-grade gliomas (LGG) samples. Among the 15 methylation probes designed for B7-H3 from Infinium HumanMethylation450 BeadChip, cg10586317 methylation exhibited the most powerful negative association with expression of B7-H3 (Pearson test, R = −.6335, P-value < 2.2 × 10 −16 ). As the IDH mutation exerted great influence on the methylation of the whole genome, we analyzed the relationship between B7-H3 and cg10586317 methylation status separately for IDH-wild and IDH-mutant gliomas.
As Figure 3A shows, in IDH-wild gliomas, methylation of cg10586317 was much lower than that of IDH-mutant tumors, as expected (Student's t test, P = 4.067 × 10 −127 ). However, in IDHwild gliomas, methylation of cg10586317 seemed to show stronger inverse correlation with B7-H3 than that of IDH-mutant gliomas (Pearson test, R = −.5935 and −.3130, respectively, Figure 3A ). The microRNA-29 family was also reported to inversely regulate B7-H3 expression. 26, 27 We further examined the correlation between expression of B7-H3 and the microRNA-29 family. As shown in Fig- ure 3B&C, the microRNA-29 family seemed to display a stronger effect on B7-H3 expression than that in glioblastoma (Pearson tests, Figure 3B&C ). These results suggested that methylation at cg10586317 loci was the potential regulatory element at higher B7- in line with what we demonstrate in Figure 3C . These results provided a clue for the puzzle in Figure 2 . In IDH-mutant grade II gliomas, methylation on cg10586317 seemed to exert 2 side effects on B7-H3 expression and microRNA-29a showed a potentially negative regulatory effect ( Figure 3G ), while in IDH-wild grade II gliomas, B7-H3 expression seemed to be downregulated by both methylation on cg10586317 and microRNA-29a (Figure 3H) , rationalizing the paradox in grade II gliomas with wild-type IDH.
| B7-H3 was associated with malignant biological process
As a checkpoint, high expression of B7-H3 was expected to confer additional malignancy to tumor cells. To explore the associated biological function, we performed GSEA network analysis using the HTSAnalyzeR package of R language. The 25 most associated biological processes and KEGG pathways were generated ( situation was similar when we took glioblastomas as an isolated entity ( Figures S4 & S5I-N) . These results implied that B7-H3 was associated with higher malignancy and might be involved in the development and/or progression of gliomas.
| B7-H3 is positively associated with the
Toll-like receptor signaling pathway
Dysregulated inflammatory response is a key characteristic of malignancies. Usually immune response is very complex, and many Figure 4E&F ). To obtain a better view of the relationship between B7-H3 and certain immune biological terms, a circos plot was generated with the circlize package. The term most related to B7-H3 was Toll-like receptor signaling pathway and the term that was least related was activation of innate immune response. We also noticed that B7-H3 expression was negatively associated with NK cell-related immune 
| B7-H3 predicts significantly worse survival for glioma patients
As B7-H3 was revealed to be associated with increased malignancy and mitigated innate immune response, we calculated the prognostic value of B7-H3 in CGGA and TCGA datasets. When taking all gliomas as a whole, higher B7-H3 expression indicated significantly worse survival ( Figure 5A&D ), and this was still the case when divided by IDH mutation status. Although in IDH-mutant gliomas of the TCGA dataset the impact was not significant, patients with higher B7-H3 expression tended to experience a shorter life expectancy. We also performed survival analysis for glioblastoma patients ( Figure 5B&E ), and Kaplan-Meier curves suggested that B7-H3 remained a prognosticator in glioblastomas, and the prognostic value became stronger when IDH-mutant glioblastomas were excluded ( Figure 5C&F) . Furthermore, the Cox proportional hazard model was generated in both CGGA and TCGA datasets. Cox regression analysis suggested that B7-H3 was an independent prognosticator for glioma patients (Table 1) .
| DISCUSSION
Recent progress in next-generation sequencing technologies has fueled the discovery of dysregulated immune function in malignant tumors. Taking advantage of the huge amount of data obtained from CGGA and TCGA projects, we performed a comprehensive analysis for B7-H3 expression in gliomas and this is, to our best knowledge, the first study characterizing B7-H3 in whole grade gliomas. Lemke et al 29 report on the role of B7-H3 in glioblastoma, and theirs is an important attempt to decipher the mechanism of B7-H3 in the deadliest type of glioma. In this study, we expanded our insights into B7-H3 by taking all diffuse gliomas as a whole into account and investigating its relationship with key molecular alterations in gliomas.
Similar to most immune checkpoints, B7-H3 expression was significantly upregulated along with tumor grade, suggesting the dysregulation of immune response in higher-grade gliomas. In molecular F I G U R E 4 Top 25 B7-H3 most related biological processes and KEGG pathways in whole grade glioma in Chinese glioma genome atlas (CGGA) (A,B) and the cancer genome atlas (TCGA) dataset (C,D). In the enrichment map for GSEA, nodes are colored by the sign of the enrichment scores (red: +, blue: −). The sizes of nodes are in proportion to the sizes of gene sets, while the width of edges is proportionate to Jaccard coefficients. B7-H3 related immune function in glioma. GSVA for immune function and relationship between B7-H3 expression and specific immune pathways in CGGA dataset and (E) and TCGA dataset (F) subtypes, we also discovered a similar expression pattern of B7-H3
to PD-L1, which was described in our previous study. 7 Moreover, the ROC curve indicated that B7-H3 can serve as a marker for mesenchymal subtype, reflecting the most profound inflammatory response in mesenchymal subtype tumors.
In the present study, we accidentally found that in grade II gliomas, B7-H3 expression was almost the same or even higher in tumors bearing IDH mutation than those that did not. This paradox As expected, B7-H3 was significantly associated with a malignant property of gliomas. Upregulation of B7-H3 indicated that the tumor was involved in dysregulated immune response and the outcome for glioma patients was dismal. The Cox proportional hazard model revealed that B7-H3 was a prognosticator independent of a series of molecular and clinical factors in both CGGA and TCGA datasets, which provided more evidence that B7-H3 may exert a strong antiimmune effect in the tumor immune microenvironment.
A recent study 30 reported that lung adenocarcinoma in eversmoking patients is associated with high B7-H3 expression and that high B7-H3 expression is associated with poor survival in ever-smoking patients, but not in nonsmoking patients. Due to a lack of smoking information in our database and TCGA database, we were not able to examine the association of smoking with B7-H3 expression and other factors of glioma. However, smoking may exert negative effects on B7-H3 expression in gliomas and quitting smoking would be of benefit to patients.
There are some limitations in our paper. First, due to the lack of methylation data and microarray data for microRNA, we were not
able to validate what we found in the TCGA dataset. Second, in subtyping patients (e.g. IDH wild-type grade II gliomas), the sample size was relatively small, which may have led to sample bias.
In past decades, the outcome of glioma patients has been improved little due to the lack of effective treatments. However, immune checkpoints, including PD-1/PD-L1, B7-H3, have emerged as promising immune treatment targets in the treatment of gliomas.
We expand our knowledge of B7-H3 by characterizing this marker at transcriptional level using vast amounts of clinical and molecular data, and offer new insight into the molecular mechanisms that underlie B7-H3 regulation, providing the basis for the development of novel therapeutic strategies.
In summary, B7-H3 expression is regulated by multiple mechanisms and is mainly involved in the T-cell receptor signaling pathway.
Higher B7-H3 expression indicates a worse prognosis for glioma patients, which warrants further research into the development of inhibitors for targeting this immune checkpoint. However, we still need to be cautious about immune checkpoint inhibition for central nervous system tumors.
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